NCT03330886View on ClinicalTrials.gov

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

March 2, 2019

Study Completion Date

March 2, 2019

Conditions
Urothelial Carcinoma
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).

Trial Locations (1)

B1610BAL

Productos Roche S.A. Quimica e Industrial, División Farmacéutica, Buenos Aires

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03330886 - A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | Biotech Hunter | Biotech Hunter